Sanofi India board in its meeting held on July 27 had approved a transaction for slump sale and transfer of its nutraceuticals business to Universal Nutriscience for a consideration of Rs 587 crore.
The transaction was closed on September 27.
During the period under review, the company has accounted for a gain of Rs 489.2 crore from the transaction, which was disclosed as an exceptional item.
The company’s revenue from operations rose to Rs 754.5 crore as compared to Rs 686.6 crore in the year-ago period.
Sanofi follows a January-December financial year.